PPT-Implementation of Precision Medicine Approaches in Intrahepatic Cholangiocarcinoma

CCF Grantee Webinar Series I 102615 Daniela Sia PhD Icahn School of Medicine at Mount Sinai Mount Sinai Liver Cancer Program Divisions of Liver Diseases New York NY danielasiamssmedu. Allyson . Merrell. Stanger Lab. November 9, 2015. The process of cholangiocarcinoma development is not fully understood. National Cancer Institute estimates there will be 35,660 . new cases . of liver cancer in 2015. From Promise to Practice. PRECISION ONCOLOGY IS THE FUTURE OF CANCER CARE.. Tumor genome data informs cancer treatment and clinical pathways, resulting in better health outcomes.. New cancer therapies target the molecular pathways that lead to tumor genesis and progression.. Targeting BAP1 mutations in intrahepatic . cholangiocarcinoma. The Cholangiocarcinoma Foundation . March 30, 2016. About Rebecca Marcus, MD. Clinical research fellow working under pre-eminent pancreatic cancer expert Dr. . Key Points. PSC is a risk factor for developing cholangiocarcinoma (CCA). Screening is controversial. Remaining in close contact and having routine visits with your healthcare team is essential to early diagnosis. Apostolia M. Tsimberidou, . MD, PhD. Professor . Investigational Cancer Therapeutics. Incorporation of Levels of Evidence into Variant Reporting/Clinical Practice. Implementation of CAP, AMP, ASCO recommendations. Monday, November 14, 2016. Session Objectives. Understand . Precision Medicine and why a diverse cohort is crucial for success. Describe the nuanced issues in Precision Medicine and genetic research as applied to Native populations. 1. 2015 Precision Medicine Initiative: . Two Components: Cancer & National Cohort. “. An emerging approach for disease prevention and treatment that takes into account people’s individual variations in genes, environment, and lifestyle”. Jeremy Warner . MD, MS. Assistant Professor of Medicine and Biomedical . Informatics. Vanderbilt University. June 26, 2017. Three questions every cancer patient asks. Who’s like me?. How long have I got?. Introduction. How Has Precision Medicine Changed the Treatment Landscape in Oncology?. Selection of Biomarkers in Drug Development. Methods to Identify Driver Mutations. Which Method Should Be Used?. Karen L. Edwards, . PhD. Professor, Dept. of Epidemiology. School of Medicine. University of . California, Irvine. Irvine, CA. Outline. Two National Initiatives . Precision Medicine Initiative . Cancer . . approach. ESDO Learning Bytes 2022. Yawen Dong . Department of Surgery. HPB . Center. , Clinic . Favoriten. Vienna, Austria. Introduction . extrahepatic. Rising incidence of . intrahepatic. CCA in the past two decades.. Biochemistry. qxsang@chem.fsu.edu. Biochemical, Molecular, and Pathological Mechanisms of Cancer, Stroke, Obesity, and Stem Cell Differentiation, and Cancer Biomarker and Drug Discovery for Precision . There is currently a lack of cholangiocarcinoma (CCA)-specific educational resources. that are . designed to support the adoption of ICD-11 among healthcare professionals and those involved in coding. . Owen Tan. 1. , Deborah Schofield. 1. , Rupendra Shrestha. 1. 1. GenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Australia.. Presenting at: .